Supplements
vitamin C treats sepsis
In plain terms: Does intravenous vitamin C help treat sepsis?
Part of: 🧪 vitamin C
No—early hopeful trials were overturned; the landmark LOVIT trial and the largest analyses show no benefit and a possible harm signal.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
High-dose intravenous vitamin C is not an established sepsis treatment and may be harmful. The evidence is genuinely mixed but nets negative: several pre-LOVIT meta-analyses of small trials reported a mortality benefit (e.g. OR 0.
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Chang et al. 2020 · Chest | RCT | mixed | moderate | RCT of HAT (hydrocortisone+vit C+thiamine): no clear mortality reduction (combination therapy — cannot isolate vitamin C). |
| Xing et al. 2021 · Clin Nutr | meta-analysis | supports | moderate | Pre-LOVIT MA: IV vit C reported beneficial for some critically-ill outcomes (later contradicted by larger trials). |
| Kanji S et al 2026 · study_type: RCT | RCT | contradicts | high | LOVIT trial PK sub-study (n=161 vitC arm). Non-survivors had higher vitC exposure than survivors (p<0.001) but on multivariable analysis exposure was NOT independently associated with 28-day mortality; only age and APACHE II were. |
| Chen Y et al 2026 · study_type: RCT | RCT | contradicts | moderate | Pilot RCT, n=40 sepsis patients. VitC reduced septic AKI incidence (25% vs 70%, p=0.004) and RRT need, but ICU mortality NOT significantly different (10% vs 15%, p=0.633). |
| Plummer & Bellomo 2022 · Nat Rev Nephrol | observational | contradicts | low | Analysis of LOVIT + CLASSIC trials: high-dose IV vitamin C might be HARMFUL in severe sepsis (higher risk of death/persistent organ dysfunction). |
| Ahmed R et al 2026 · study_type: meta-analysis | meta-analysis | mixed | moderate | Systematic review 2020-2025, 5 studies (RCTs, cohorts, meta-analyses). Modest physiologic benefits (SOFA, vasopressor duration) but 'consistent improvement in mortality...remains unproven.' |
| Brown et al. 2022 · Cureus | meta-analysis | contradicts | moderate | SRMA (18 studies, 4078 pts): no mortality reduction and no effect on SOFA, ICU stay, vasopressor or ventilation duration. |
| Vera-Ponce VJ et al 2026 · study_type: meta-analysis | meta-analysis | mixed | high | Umbrella review, 31 SRs. Combination regimens (HAT, vitC+thiamine) did NOT reduce mortality. Monotherapy: possible mortality-benefit signal only under narrow conditions, low-to-moderate certainty. |
| Feng et al. 2021 · Sci Prog | meta-analysis | supports | low | Pre-LOVIT MA (9 RCTs, 584 pts): vit C reduced 28-day mortality (OR 0.60) — the earlier optimistic signal, since overturned. |
| Lee et al. 2023 · Ann Intensive Care | meta-analysis | supports | moderate | Updated SRMA + trial-sequential analysis of IV vit C monotherapy: the landmark LOVIT harm signal reverses earlier positive pooled estimates. |
| Radke et al. 2023 · Curr Opin Crit Care | observational | contradicts | low | Review of high-dose vitamin C monotherapy in critical illness: recent RCT evidence negative — 'end of the story' for routine use. |
| Alangari A et al 2026 · study_type: meta-analysis | observational | contradicts | moderate | PRISMA-informed review of high-dose IV vitC (2010-2025), prioritizing RCTs/SRs. Conclusion: 'evidence does not support routine use of high-dose IVC in sepsis'; risks include oxalate nephropathy, hemolysis in G6PD deficiency. |
| Fujii et al. 2022 · Intensive Care Med | meta-analysis | contradicts | high | Component NMA (43 RCTs, 10,257 pts, CINeMA): vitamin C alone or in metabolic-resuscitation combos NOT associated with lower longer-term mortality; no effect on organ dysfunction or ICU stay. |
| Hung et al. 2023 · Front Nutr | meta-analysis | mixed | moderate | MA + TSA of IV vit C monotherapy on mortality: information size insufficient — no firm mortality benefit established. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.